ImmunoBodies™ vaccines are based on recombinant fusion proteins and facilitate uptake of viral antigens by dendritic cells (DC). ImmunoBodies comprise two key functional components: the Fc region of human IgG1 immunoglobulin region that binds to FcγRI (CD64) on DCs and the virus-derived antigen that is processed by DCs and presented on both MHC class I and class II. ImmunoBodies are thus designed to target recombinant antigens to DCs to facilitate stimulation of both CD4 and CD8 T-cell immune responses. They mimic immune complexes by incorporating the antigen-antibody complex in a single molecule.
Additional information on this technology is provided in the publication highlighted.